4D Molecular Therapeutics, Inc. (FDMT) NASDAQ
9.53
+0.26(+2.80%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
9.53
+0.26(+2.80%)
Currency In USD
Address
5858 Horton Street
EmeryVille, CA 94608
United States of America (the)
Phone
510 505 2680
Sector
Healthcare
Industry
Biotechnology
Employees
227
First IPO Date
December 11, 2020
| Name | Title | Pay | Year Born |
| David H. Kirn | Co-Founder, President, CEO & Director | 1.23M | 1963 |
| Kristian Humer | CFO and Principal Financial & Accounting Officer | 116,247 | 1976 |
| John F. Milligan | Executive Chairman | 150,000 | 1961 |
| Noriyuki Kasahara | Chief Scientific Advisor & Member of Scientific Advisory Board | 201,288 | 1963 |
| Theresa Janke | Co-Founder & Chief of Staff | 652,315 | 1975 |
| Fariborz Kamal | Chief Technical Advisor | 892,868 | 1963 |
| An Song | Chief Translational Medicine Advisor | 0 | N/A |
| Scott Bizily | Chief Legal Officer & Corporate Secretary | 0 | 1972 |
| Julian Pei | Head of Investor Relations & Corporate Finance | 0 | N/A |
| Ashoo Gupta | Principal Accounting Officer & Principal Financial Officer | 0 | 1976 |
| Katy Barglow | Chief Technical Officer | 0 | N/A |
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.